Skip to search formSkip to main contentSkip to account menu

LY 295501

Known as: LY-295501, LY295501 
National Institutes of Health

Related topics

Related topics

1 relation
ILX295501

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Epilogue
The last time I saw Jerry Grindey, it was early in the 84th Annual Meeting of the American Association for Cancer Research. We… 
1999
1999
Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system.
The diarylsulfonylureas (DSUs) are a novel class of cytotoxic agents with high potential for activity. LY295501 is one of the… 
1999
1999
Determination of LY295501 in human plasma by reverse phase HPLC with UV detection.
1998
1998
MASS SPECTROMETRY IDENTIFICATION OF NOVEL METABOLITES OF THE MULTIDRUG RESISTANCE MODULATOR LY 335979 IN RAT BILE AND HUMAN LIVER MICROSOMAL INCUBATIONS
Compound LY335979 is a P-glycoprotein inhibitor currently entering phase I clinical trials for potential reversal of multidrug… 
1997
1997
Disposition and metabolism of the sulfonylurea oncolytic agent LY295501 in mouse, rat, and monkey.
The disposition and metabolism of LY295501 was studied in mice, rats, and monkeys. This novel diaryl sulfonylurea oncolytic agent… 
1997
1997
FLAG epitope positioned in an external loop preserves normal biophysical properties of CFTR
Schultz, Bruce D., Akira Takahashi, Chongguang Liu, Raymond A. Frizzell, and Marybeth Howard. FLAG epitope positioned in an… 
Highly Cited
1993
Highly Cited
1993
Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.
Human pancreatic carcinoma xenograft models were developed from established MIA PaCa-2 and PANC-1 cell lines (ATCC, Rockville, MD… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)